In the phase 3 SIERRA trial, high rates hematopoietic cell transplantation were observed in patients with relapsed/refractory acute myeloid leukemia who underwent 131-iodine conditioning.
In patients with relapsed/refractory acute myeloid leukemia conditioned with 131-iodine (Iomab-B). high rates of allogeneic hematopoietic cell transplantation (HCT) were observed, despite lack of a complete response (CR) following standard therapies, according to results of the phase 3 SIERRA trial (NCT02665065) presented during the 2022 Transplantation & Cellular Therapies Meeting.
Patients achieved 100% neutrophil and platelet engraftment after Iomab-B conditioning and allogeneic HCT. Patients also had a lower incidence of sepsis on this treatment regimen.
A total of 153 patients were enrolled and randomized 1:1 to either the Iomab-B HCT group (n = 76) or the conventional care group (n = 77). In the conventional care group, those who achieved a CR when on to receive HCT or physician’s choice standard of care. Those who did not achieve a CR could cross over to the Iomab-B group (n = 40).
Patients needed to be 55 years or older with a Karnofsky performance score of 70 or more. Additionally, patients needed to have a human leukocyte antigen (HLA)–matched related or unrelated donor, and experienced primary induction failure. The primary end point was durable complete remission at 6-months, and the secondary end point was overall survival.
Between days 7 and 12, patients received a 20 mCi or less dosimetric dose followed by imaging and 24 Gy of Iomab-B to the liver. After day 12, patients received 30 mg/m2 of fludarabine daily and 200 cGy of total body irradiation followed by HCT.
The median age was 65.0 years vs 66.1 years in the Iomab-B and conventional care groups, respectively. The majority of patients in the experimental and control arms, respectively, had adverse (60.5% vs 62.3%) cytogenetic and molecular risk, while others had favorable (5.3% vs 3.9%), intermediate (32.9% vs 33.8%) risk. In terms of disease status at randomization, the majority of patients in both respective groups experienced primary induction failure (56.6% vs 50.6%), and others had first early relapse (22.4% vs 27.3%), had relapse/refractory disease (14.5% vs 15.6%), and had second relapse (6.6% vs 6.5%). Additionally, patients in the Iomab-B group had a median of 30% (95% CI, 4%-97%) marrow blasts at randomization compared with 19.5% (95% CI, 2.8%-97.4%) in the conventional care group.
Prior to enrollment on the trial, 66% of patients received targeted therapies, with 66% of those patients receiving venetoclax (Venclexta)-based therapy with a median of 3 prior regimens. Of those in the conventional care group, 47% had received prior targeted therapy, 81% of which were venetoclax-based. Treatment was unsuccessful in 50% of patients who were allowed to cross over to receive Iomab-B.
Of the 76 patients in the Iomab-B group, 66 received HCT. Of the 77 patients in the conventional care group, 14 received standard of care HCT. The median Iomab-B activity in the experimental group compared with the control group that crossed over was 649.5 mCi vs 606.5 mCi. Patients had a median dose to marrow of 15.9 Gy vs 16.1 Gy in the Iomab-B group and in the control group for those who crossed-over. The median number of days to absolute neutrophil count (ANC) and platelet engraftment was 14 days and 17 days in the Iomab-B arm, 13 and 17 days in the crossover arm, and 16 and 14 days in the standard of care arm, respectively. Only 1 case of engraftment failure was reported in the standard of care arm.
On day 100 or more, the non-relapse mortality occurred in 6 of 65 evaluable patients in the Iomab-B group, 2 of 40 in those who crossed-over, and 2 of 14 in those who achieved a CR in the conventional care group.
In terms of notable grade 3 or higher adverse effects (AEs) occurred in 10% or more of patients, the most significant was sepsis (P = .002), which occurred in 5.3% of patients in the Iomab-B group, and 23.7% of those in the conventional care group. Other common AEs in both respective groups included febrile neutropenia (33.3% vs 44.7%), mucositis (12.0% vs 11.8%), hypertension (12.0% vs 13.2%), and pneumonia (8.0% vs 13.2%). Device related infection was observed in 5.3% of patients in the Iomab-B group, and 2.6% in the conventional care group. Additionally, a small portion of patients experienced acute kidney injury (4.0% vs 2.6%), and venoocclusive liver disease (1.3% vs 0.0%) between both groups, respectively.
Reference
Gyurkocza B, Nath, R, Seropian SE, et al. High rates of transplantation in the phase III SIERRA trial utilizing anti-CD45 (Iodine) 131I-Apamistamab (Iomab-B) conditioning with successful engraftment and tolerability in relapsed refractory (R/R) acute myeloid leukemia (AML) patients after lack of response to conventional care and targeted therapies. Presented at the 2022 Tandem Meeting; April 22-26, 2022; Salt Lake City, UT. Abstract 40.
BLA for Remestemcel-L to Treat Pediatric SR-aGVHD Resubmitted to FDA
July 10th 2024The application of remestemcel-L, a potential first-of-its-kind treatment for pediatric patients following stem cell transplants, has been resubmitted for FDA approval after addressing previous concerns.
Read More
Novel Therapy Boosts Survival After Stem Cell Transplants
July 3rd 2024Alexandra Gomez Arteaga, MD, discussed findings from a retrospective study comparing Orca-T with posttransplant cyclophosphamide graft-vs-host disease prophylaxis to assess outcomes in patients undergoing hematopoietic cell transplant.
Read More
Ponatinib, Chemo, and Transplant Shows Promise for Long-Term Survival in Ph+ ALL
June 20th 2024The phase 2 PONALFIL trial evaluating a ponatinib regimen shows promise for long-term survival in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More